Chimerix (NASDAQ:CMRX – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
Chimerix (NASDAQ:CMRX – Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Chimerix Stock Performance
Chimerix stock traded down $0.00 during midday trading on Thursday, hitting $0.91. 98,717 shares of the company’s stock were exchanged, compared to its average volume of 391,194. Chimerix has a 12-month low of $0.88 and a 12-month high of $1.57. The stock has a market cap of $80.74 million, a price-to-earnings ratio of -0.98 and a beta of 1.15. The firm’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $1.00.
Analysts Set New Price Targets
Check Out Our Latest Research Report on Chimerix
About Chimerix
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
- Five stocks we like better than Chimerix
- Dividend Capture Strategy: What You Need to Know
- Hasbro’s Management Made All the Right Calls This Quarter
- The 3 Best Blue-Chip Stocks to Buy Now
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Financial Services Stocks Investing
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.